A new era for sunscreen?

Newsletters Dark mode

Plus: NAD+ and retinal health, GLP-1s, labor timing, and brain plasticity.

to the archive

Sunday, July 19, 2026

Elysium Health announces the FDA's approval of a new sunscreen active ingredient, bemotrizinol, for the first time in decades. The company offers expert commentary from Dr. Richard Granstein on the benefits of bemotrizinol, which provides broad-spectrum protection against UVA and UVB rays. Elysium Health also highlights other research topics in its July edition of The Abstract.

Read this email as text

for screen readers, or when images don't load

Thanks for reading The Abstract. This month’s edition is 1,083 words, about a 4-minute read.

Is there a topic that you’d like to see more of in The Abstract? Drop us a line at [email protected]. Want to get The Abstract in your inbox? Sign up here.

Summer is peak sunscreen season, and this month brought a notable update: The FDA approved a new sunscreen active ingredient for the first time in decades. We offer expert commentary from Dr. Richard Granstein, a world-renowned leader in the field of dermatology and member of the Elysium Scientific Advisory Board. Also in the July edition of The Abstract: new research on NAD+ and retinal cell resilience, placental metabolism and the timing of labor, whether GLP-1 medications may have a role in longevity, and how brain health can improve across adulthood.

FDA approves a new sunscreen ingredient for the first time in decades

Email headers

sender, ESP fingerprints, unsubscribe and auth headers

As received, minus the delivery side: the archive's own addresses appear as [recipient], relay hops and signatures are left out, and unsubscribe links are trimmed to their host.

Received-SPF: pass ([receiver]: domain of [recipient]@send.elysiumhealth.com designates 167.89.72.22 as permitted sender) receiver=[receiver]; client-ip=167.89.72.22; envelope-from="[recipient]@send.elysiumhealth.com"; helo=o1280.shared.klaviyomail.com;
Authentication-Results: [receiver]; dkim=pass header.d=elysiumhealth.com header.s=kl2 header.b=nTYI/ngW; dmarc=pass header.from=elysiumhealth.com policy.dmarc=quarantine; spf=none ([receiver]: no SPF records found for [email protected]) smtp.helo=o1280.shared.klaviyomail.com; spf=pass ([receiver]: domain of [recipient]@send.elysiumhealth.com designates 167.89.72.22 as permitted sender) smtp.mailfrom=[recipient]@send.elysiumhealth.com; arc=none smtp.remote-ip=167.89.72.22
Content-Type: multipart/alternative; boundary=693fbe31292dca7c51c032aa02c8a3773e1ac71536a40335569f71ad00c8
Date: Sun, 19 Jul 2026 12:00:38 +0000 (UTC)
From: Elysium Abstract <[email protected]>
Mime-Version: 1.0
Message-ID: <4e101m8yT3u59FyNNTjVsw@geopod-ismtpd-21>
Subject: A new era for sunscreen?
Reply-To: [email protected]
List-Unsubscribe: <https://manage.kmail-lists.com/…>
List-Unsubscribe-Post: List-Unsubscribe=One-Click
X-Kmail-Account: R8xQKv
X-Kmail-Message: 01KXRVGVXWR1325X9KRPPAJNFX
X-Kmail-Ops: 01KX28G5HSKQA9CNV085MJW4AC
X-Report-Abuse: Please report any spam or abuse to: [email protected]
X-SG-EID: u001.Xv32TvI6iuV+tZ4vlqHO3HOP0TVxYBknYAX4/Mby5Th0PYwVlaUDVZEfaaXcBa1/i/If+231cWgIYCosFVQxSCNYYl6BGiqU2eWIsl3cko4bWKxUBEmWOc2WZZ3sjdjeV9puYMSnEqKan6JhUo7BAfwyTiG+NRCgYo/z/xNNhqzcu38WfKaRnzffTT8weN3UbZYqn7MOhmRF0tdhxSYqzaYyCbmJI2OmDrbxNikQO/+gkmsx9ufrv5+OyPVBXiBY
X-SG-ID: u001.SdBcvi+Evd/bQef8eZF3BiU3Zi1S53GtqGa3TWBmqe75yn5aYrkvkfG+ZGKrHRvqHEqNnYhXzKEMbIPUuNbUdfpjphyJI24ahdp5cMyD+gtd10HMsYQGG+9KCgoFZ++5usaE1rO9s7wHD0xpqN9fPZSfd0raNCPr6x9v52fVvY9diIXzZKlpjDU7+a0x/IpdEM0gUz+nwIauzjD2pB+V3roY+TT8pUndtRVZmRcv6ATHsaGWdjGZViuJP7NQj4fA3hMt73HOZeRrK2zqh3LVVDzTo5+WdoIXzpTPUT2KFVDBA6KSytUIoyenQcZRhLh8azHd+o/TMqkk88BOkCk91kQGQp8M6erEge1TVf1RbwkpG1dP27oeHFPbHczGbNQG
X-Entity-ID: u001.lP8bpbcNOc7n5/pI/ei+9g==

Archived for reference and commentary. Elysium Health, its logos and content are the property of their respective owners; Inbox Archive claims no affiliation and has disabled all links. If you own this content and would like it removed, get in touch.